Bonti is a rapidly emerging biotechnology enterprise founded by world class neurotoxin experts with proven success at one of the Fortune 500 fastest growing pharma companies.  Our focus is on developing novel treatment paradigms driven by our unique neurotoxin platform.  We are targeting both aesthetic and therapeutic indications with strong unmet needs not currently addressed by existing marketed products.

Our lead product candidate, Bonti EB-001, has multi-billion dollar addressable market opportunities. EB-001 is a botulinum neurotoxin which has, one, a mechanism of action similar to currently marketed neurotoxin products and, two, a differentiated clinical profile.

Learn how our molecule works and why it will excel in our targeted aesthetic and therapeutic markets.

Click here to view our demonstration.

Bonti Appoints Jonathan Lim and Tom Albright to the Board of Directors
Bonti Raises additional $2 Million Through Capital Term Loan from Silicon Valley Bank
Bonti Completes $8.9 Million Series A Funding to Advance Pipeline of Novel Neurotoxin Therapeutics